Crossmark

The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair–proficient colorectal cancer: preliminary results of a phase 2 study

Crossref DOI link: https://doi.org/10.1007/s00384-025-04806-z

Published Online: 2025-01-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Ying

Wang, Jufeng

Fang, Yong

Deng, Yanhong

Hu, Changlu

Fan, Qingxia

Gu, Kangsheng

Zhang, Yu

Yang, Chen

Liu, Zhenru

Tian, Ji

Sun, Xiyang

Sun, Shuguang

Cheng, Ying
License Information

Text and Data Mining valid from 2025-01-21

Version of Record valid from 2025-01-21
More Information

Article History

Accepted: 6 January 2025

First Online: 21 January 2025

Declarations

:

: The protocol underwent approval by the ethics committee at each of the investigative sites.

: Informed consent was mandatory and obtained from all enrolled patients.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below